|
|
Volumn 15, Issue 6, 1999, Pages 1233-1238
|
|
Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
PACLITAXEL;
TOPOTECAN;
ADULT;
AGED;
ARTICLE;
CLINICAL TRIAL;
COMPARATIVE STUDY;
FEMALE;
FOLLOW UP;
HUMAN;
LUNG TUMOR;
MALE;
MIDDLE AGED;
MORTALITY;
MULTICENTER STUDY;
OVARY TUMOR;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PROGNOSIS;
SALVAGE THERAPY;
SMALL CELL CARCINOMA;
SURVIVAL;
SURVIVAL RATE;
TIME;
TREATMENT OUTCOME;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
CARCINOMA, SMALL CELL;
CLINICAL TRIALS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
MULTICENTER STUDIES;
OVARIAN NEOPLASMS;
PACLITAXEL;
PROGNOSIS;
SALVAGE THERAPY;
SURVIVAL ANALYSIS;
SURVIVAL RATE;
TIME FACTORS;
TOPOTECAN;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 0033451255
PISSN: 10196439
EISSN: None
Source Type: Journal
DOI: 10.3892/ijo.15.6.1233 Document Type: Article |
|
Times cited : (70)
|
|
References (0)
|
